
ANTI-SEIZURE MEDICATION

If you think a patient should be maintained on a specific manufacturer's product, prescribe either by specifying brand name or by using the generic drug name and name of the manufacturer. 1




who struggle to swallow tablets/capsules.



Below are the brand leader or originator of the currently licensed anti-seizure medication for treating epilepsy in children and adults and alternative formulations available for those unable to swallow tablet or capsules. The size and shape of tablets and capsules can impact on a patient's ability to swallow them. The photos and measurements of the tablets and capsules are there to aid formulation choice. Please note that generic versions of these products are available for most actives, but they may differ in size and shape.

CATEGORY 3¹

For these drugs, it is usually unnecessary to ensure that patients are maintained on a specific manufacturer's product unless there are specific reasons such as patient anxiety and risk of confusion or dosing errors.







UNCLASSIFIED ANTI-SEIZURE MEDICATION

Acetazolamide Tablets

of Injection

Oral Solution

Diazepam Tablets

There are 5 products that are used in the treatment of epilepsy that do not fall into any of the MHRA categories.

Rectal Solution

Oral Solution

Oral Suspension

Diazepam Injection



VIGABATRIN

Soluble Tablets

2.5mg, 5mg, 7.5mg & 10mg

Piracetam Tablets

800mg, 1200mg

Sabril Tablets





Supporting healthcare professionals, patients and their families and carers through educational resources

WE KNOW ...

That for anti-seizure medications (ASMs), the choice of active ingredient is important... ... but so is the formulation.

WHICH MEANS ...

- For new ASM initiations, there should be an informed decision made on the best formulation of the chosen active ingredient in order to optimise the outcomes for that patient.
- Not all formulations contain the same excipients. Excipients are particularly important for children, for example products may contain alcohol, colouring agents or preservatives. See Swallowingdifficulties.com below for more information.
- For continuity of care, the specialist's choice of formulation should be adhered to on renewing and fulfilling the prescription.
- On reviewing patients if they are not seizure free - consideration should be given to whether they are on the optimal formulation of that active ingredient to optimise their outcomes.





For more information on the types and amounts of "excipients of concern" in each product. www.swallowingdifficulties.com



Children and young people with epilepsy can fee frightened, lonely and the condition is often misunderstood. We're here for you. www.youngepilepsy.org.uk



Transforming the lives of people with epilepsy through world-leading research, advocacy and care. www.epilepsysociety.org.uk

FORMULATION KEY

















The development of this poster was funded by Desitin Pharma. We would like to thank Day Lewis for their support in the photography of the medicines.

DIC: UK/CP/0523 **DOP:** February 2023 (All information is correct as of the time of producing this poster – February 2023)